Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.

© Humphrey Lab
SETD2-deficient kidney cancer cells, courtesy of Humphrey group, Department of Oncology, University of Oxford